Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorFujian Cancer Hospital
About this trial
The objective of this clinical trial is to understand whether triethanolamine cream can prevent and treat acute radiation vaginitis. It will also learn about the safety of triethanolamine cream. The main questions it aims to answer include:
Can triethanolamine cream reduce the incidence and severity of radiation vaginitis in cervical cancer patients undergoing radiotherapy?
What medical problems might participants encounter when using triethanolamine cream?
Researchers will compare triethanolamine cream with routine care to observe whether triethanolamine cream will reduce the incidence and severity of radiation vaginitis in cervical cancer patients receiving radiotherapy.
Participants will:
Daily vaginal administration of triethanolamine cream, vaginal opening application and routine care, or only routine care, from the first day of radiotherapy until 28 days after the end of radiotherapy.
Four examinations were conducted respectively from before radiotherapy to 90 days after its end.
Record their symptoms and conduct injury scoring.
Eligibility criteria
Qualifiers
Age 18-75 years old;
Those diagnosed with cervical cancer by histological pathology and receiving radiotherapy with a total radiation dose of ≥70Gy;
ECOG score: 0-2 levels;
Normal mental state and clear consciousness;
Disqualifiers
Those with severe immune deficiency (such as those who have recently received bone marrow transplantation, with long-term high-dose glucocorticoids > 20 mg/ day for more than 2 weeks);
Congenital vaginal malformations;
Patients who are pregnant, breastfeeding, or have plans and the possibility of becoming pregnant;
Other conditions that the researcher deems unsuitable for enrollment (such as: previous allergy history to triethanolamine cream, etc.).
Trial design
Treatments tested in this trial
- Trolamine (Biafine)
Treatment groups
238 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov